MOUNTAIN VIEW, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that company President and CEO Thomas B. King will present during the 11th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2009 at 2:45 p.m. ET. The presentation will be webcast from the Waldorf-Astoria Hotel in New York, NY.
To access the presentation via the Web, please go to the Investor Relations tab at www.alexza.com or at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ALXA&item_id=2079439. A replay of the webcast will be made available approximately 24 hours after the live presentation and the replay will be archived for 14 days.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.
Alexza's lead program is AZ-004 (Staccato loxapine) and is being developed
for the acute treatment of agitation in schizophrenic or bipolar disorder
patients. Alexza has completed and announced positive results from both of
its AZ-004 Phase 3 clinical trials, and is projecting a New Drug Application
submission in early 2010.
|SOURCE Alexza Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved